Navigation Links
New collaboration to develop treatments for liver disease
Date:9/7/2012

A new collaboration based at the University of Cambridge will aim to discover and develop new medicines to treat liver disease.

The partnership, between the University and global pharmaceutical company GlaxoSmithKline (GSK), will build upon the work of researchers who have identified a molecular mechanism that plays a major role in the life-threatening liver disease that develops in a population of patients with a particular mutant gene.

Alpha-1 antitrypsin (A1AT) deficiency is one of the most common genetic disorders in the UK, affecting approximately one in 2,000 people. The A1AT protein is produced mainly in the liver and circulates to the lungs, where it serves a protective function against enzymes which can break down lung tissue.

In patients with A1AT deficiency, the protein cannot circulate freely and accumulates in the liver, leading to potentially life-threatening liver conditions including neonatal hepatitis, cirrhosis and hepatocellular carcinoma. Additionally, without A1AT circulating to the lungs, lung tissue can break down, predisposing patients to early onset emphysema. Currently, the only available treatments are liver transplantation for cirrhosis and protein replacement therapy for emphysema.

The mechanism that underlies protein accumulation in the livers of individuals with A1AT deficiency has been defined by the team led by Professor David Lomas in the University's Cambridge Institute for Medical Research (CIMR). The collaboration with GSK will combine Professor Lomas' long-term research with GSK's expertise in drug discovery and development in order to develop new therapeutics. Work on the project will be carried out both at GSK and at the CIMR.

"Currently, the only option for patients with liver disease as a result of alpha-1 antitrypsin deficiency is transplantation," said Professor Lomas. "This partnership brings together our collective expertise in target biology and drug discovery to tackl
'/>"/>

Contact: Sarah Collins
sarah.collins@enterprise.cam.ac.uk
44-122-376-0335
Cambridge Enteprise University of Cambridge
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Mayo Clinic, Dartmouth-Hitchcock announce collaboration
2. Treating the whole person with autism sets direction for parent-clinician collaboration
3. Astex, CRT and the Institute of Cancer Research announce epigenetic drug discovery collaboration
4. Researchers develop a new cell and animal model of inflammatory breast cancer
5. Scientist awarded $1 million grant to develop tools for hepatitis C treatment discovery
6. 2 genetic deletions in human genome linked to the development of aggressive prostate cancer
7. Kudos for 3 NJIT Enterprise Development Center high-tech companies
8. Study: Women not getting enough exercise; at risk of developing metabolic syndrome
9. Online Tool Could Diagnose Autism Quickly, Developers Say
10. Discovery could help to develop drugs for organ transplant and cancer patients
11. 2 repressor genes identified as essential for placental development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... September 01, 2015 , ... The Capillus82™ ... treatment of androgenic alopecia in adults, announces Miami-based medical device manufacturer, Capillus, LLC. ... also demonstrating its safety when used at home to combat hair loss. ...
(Date:9/1/2015)... ... 2015 , ... According to a study published August 25th in ... in a three year study about weight loss and diabetes were far more likely ... loss surgery at the onset of the trial. In fact, the participants in the ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... differently. If not managed, stress created from everyday life changes can lead to ... herbs that provide support for coping with stress. Herbal supplement manufacturer MediHerb ...
(Date:9/1/2015)... ... , ... Philanthropic giving in the U.S. has been stuck at 2% GDP ... 2015, released today by Camber Collective, goes to the root of this problem and ... $22B in new philanthropic giving and shift $25B that’s already being donated, according to ...
(Date:9/1/2015)... ... September 01, 2015 , ... Pharmaceutical ... different malignancies. Some options for cancer treatment are available belonging to various ... approach is necessary for effective treatment. Several molecules have been discovered out ...
Breaking Medicine News(10 mins):Health News:Capillus82™ Laser Therapy Cap Receives FDA Clearance for Treatment of Hair Loss 2Health News:Recent Journal Article on Diabetes Remission Adds to the Growing Pile Of Evidence in Favor of Bariatric Surgery, Says Dr. Feiz and Associates 2Health News:MediHerb Launches New Herbal Supplement to Help with the Challenges of Everyday Life 2Health News:MediHerb Launches New Herbal Supplement to Help with the Challenges of Everyday Life 3Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 2Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 3Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 2Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 3
... WHAT: City of Hope and Santa Fe Communications ... Vida campaign to support City of Hope, a ... other,life-threatening diseases. The campaign will encourage community members ... year,s activities,will include public service announcements, community events ...
... Finds Optimal Outcomes, Can Be Achieved ... INDIANAPOLIS, July 8 Compliance with ... as measured by,reduced emergency room visits and ... by HealthCore, Inc., the health outcomes,research subsidiary ...
... (PHILADELPHIA) Scientists at the Kimmel Cancer Center at Thomas Jefferson ... the mechanism of breast cancer metastasis, the process by ... or DACH1, they are beginning to pinpoint new therapeutic ... their findings in the Proceedings of the National ...
... age of American moms may be behind increase in cases, ... heart attacks are rare among young women, becoming pregnant does ... , "This is a unique phenomenon in the sense ... have [heart attacks]," said lead researcher Dr. Uri Elkayam, a ...
... Reform to Individual,Health Plan Market, According to ... Tenn., July 8 HealthLeaders-InterStudy, a,leading provider ... Blue,Cross Blue Shield of Michigan,s proposed package ... and allowing the insurer,s for-profit,subsidiaries to expand ...
... Vascular Surgeon-Scientist Ulka Sachdev, M.D., Named 2008 Wylie ... The Foundation for,Accelerated Vascular Research (FAVR) today ... of Pittsburgh,Medical Center, has been named the 2008 ... grant was awarded to support her research,in understanding ...
Cached Medicine News:Health News:Paul Rodriguez, Voces Del Rancho and More to Be Honored at the 8th Annual Angels of Hope Awards, July 12 2Health News:Study Measures Real-World Comparative Effectiveness of Asthma Controller Medications 2Health News:Study Measures Real-World Comparative Effectiveness of Asthma Controller Medications 3Health News:Study Measures Real-World Comparative Effectiveness of Asthma Controller Medications 4Health News:Jefferson researchers show antibody to breast cancer-secreted protein blocks metastasis 2Health News:Jefferson researchers show antibody to breast cancer-secreted protein blocks metastasis 3Health News:Pregnancy Boosts Heart Attack Risk 2Health News:Blue Cross Blue Shield of Michigan's Proposed Reforms Make Little Progress With State Senate 2Health News:The Foundation for Accelerated Vascular Research Grants $150,000 Wylie Scholar Award for Blood Vessel Research 2Health News:The Foundation for Accelerated Vascular Research Grants $150,000 Wylie Scholar Award for Blood Vessel Research 3
(Date:9/1/2015)... SPRINGDALE, Ark. , Sept. 1, 2015 NOWDiagnostics Inc., ... completed its acquisition of ZBx Corporation of Canada ... to its vision of a world where people have ... NOWDiagnostics manufactures and sells a line of unique blood-based ... simple-to-use, highly accurate tests for a variety of ailments ...
(Date:9/1/2015)... 1, 2015 UT Southwestern Medical Center President ... members joined U.S. Representatives Michael C. Burgess , ... discussion on the 21 st Century Cures Act, ... considered by the United States ... Academy of Sciences members, department chairs, center directors, and ...
(Date:9/1/2015)... Sept. 1, 2015  Results from an interim analysis ... that 5g of idarucizumab enabled emergency surgery to ... treated with dabigatran (Pradaxa ® dabigatran etexilate ... effect of dabigatran enabled patients to be urgently ... of 1.7 hours between administration of idarucizumab and ...
Breaking Medicine Technology:NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 2NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 3U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 2U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 3U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 4U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 5New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 2New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 3New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 4New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 5New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 6New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 7New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 8New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 9
... in wake of AHA-presented data , ... a clinical trial suggesting rosuvastatin may lower the cardiovascular risk ... statin use in older adults, according to a national poll ... the online poll conducted by medical news site MedPage Today ...
... FRANCISCO, Calif., Nov. 25 Poniard,Pharmaceuticals, Inc. (Nasdaq: ... on,innovative oncology therapies, announced today that it will ... in order to allow,the Company to focus its ... product candidate, and to support the initial commercialization ...
Cached Medicine Technology:Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 3Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 2Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 3
... Right Solution For Your Tracheostomy Care Needs, ... tray features the latest components for efficient ... control task. Designed by clinicians, these latex-free ... each patient and caregiver. All of our ...
... Right Solution For Your Tracheostomy Care Needs, ... tray features the latest components for efficient ... control task. Designed by clinicians, these latex-free ... each patient and caregiver. All of our ...
... alternate care facilities with a wide ... offer the finest in nursing convenience ... guidance of experienced nursing personnel, these ... is required for efficient and quick ...
... alternate care facilities with a wide ... offer the finest in nursing convenience ... guidance of experienced nursing personnel, these ... is required for efficient and quick ...
Medicine Products: